Cannabinoids in the treatment of cancer

Cancer Letters

Volumn 285, Issue 1, 2009, Pages 6-12

  Alexander, Amy ^a   Smith, Paul F ^a   Rosengren, Rhonda J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cannabinoids; CB1; CB2; JWH 133; MAPK

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABIDIOL; CANNABINOID; CANNABINOL; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; LY 109514; NABILONE; PERTUSSIS TOXIN; RIMONABANT; UNCLASSIFIED DRUG; WORTMANNIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BINDING AFFINITY; BREAST CANCER; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER THERAPY; CELL CYCLE ARREST; CELL SURVIVAL; CLINICAL TRIAL; DOWN REGULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE RESPONSE; LEWIS CARCINOMA; MELANOMA; MELANOMA B16; METASTASIS INHIBITION; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR GROWTH;

CANNABIS SATIVA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZOXAZINES; BREAST NEOPLASMS; CANNABINOIDS; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMANS; MALE; MORPHOLINES; NAPHTHALENES; NEOPLASMS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 70349289122     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.005     Document Type: Review

References (51)

1. Gaoni D., and Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86 (1964) 1646-1647
2. Elsohy M.A., and Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78 (2005) 539-548
3. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1947
4. Wilson R.I., and Nicoll R.A. Endocannabinoid signaling in the brain. Science 296 (2002) 678-682
5. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
6. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
7. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
8. Felder C.C., and Glass M. Cannabinoid receptors and their endogenous agonists. Ann. Rev. Pharmacol. Toxicol. 38 (1998) 179-200
9. Pertwee R.G. Cannabinoid pharmacology: the first 66 years. Br. J. Pharmacol. 147 (2006) S163-S171
10. Guzman M. Cannabinoids: potential anticancer agents. Nat. Rev. Cancer 3 (2003) 745-755
11. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., and Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 2008 (2008) 339-342
12. Glass M., and Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 56 (1999) 1362-1369
13. Demuth D.G., and Molleman A. Cannabinoid signalling. Life Sci. 78 (2006) 549-563
14. Tramer M.R., Carroll D., Campbell F.A., Reynolds J.M., and Moore R.A. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. Br. Med. J. 323 (2001) 16-21
15. Munson A.E., Harris L.S., Friedman M.A., Dewey W.L., and Carchman R.A. Antineoplastic activity of cannabinoids. J. Natl. Cancer Inst. 55 (1975) 597-602
16. Galve-Roperh I., Sanchez C., Cortez M.L., Gomez del Pulgar T., Izquierdo M., and Guzman M. Antitumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med. 6 (2000) 313-319
17. Sanchez C., de Caballos M.L., Gomez del Pulgar T., Rueda D., Corbacho C., Velasco G., Galve-Roperh I., Huffman J.W., Cajal S.R., and Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB (2) cannabinoid receptor. Cancer Res. 61 (2001) 5784-5789
18. Casanova M.L., Blazquez C., Martinex-Palacio J., Villanueva C., Fernandez-Acenero M.J., Huffman J.W., Jorcano J.L., and Guzman M. Inhibition of skin tumour growth and angiogenesis in vivo by activation of cannabinoid receptors. J. Clin. Invest. 11143-50 (2003)
19. Blazquez C., Carracedo A., Barrado L., Real P.J., Fernandez-Luna J.L., Velasco G., Malumbres M., and Guzman M. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20 (2006) E2199-E2208
20. Carracedo A., Gironella M., Lorente M., Garcia S., Guzman M., Velasco G., and Iovanna J.L. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 66 (2006) 6748-6755
21. Cianchi R., Papucci L., Schiavone N., Lulli M., Magnelli L., Vinci M.C., Messerini L., Manera C., Ronconi E., Romagnani P., Donnini M., Perigli G., Trallori E., Capacciloi S., and Masini E. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de nono synthesis in colon cancer cells. Clin. Cancer Res. 14 (2008) 7691-7700
22. Bifulco M., Malfitano A.M., Pisanti S., and Laezza C. Endocannabinoids in endocrine and related tumours. Endocr. Relat. Cancer 15 (2008) 391-408
23. Bifulco M., Laezza C., Pisanti S., and Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br. J. Pharmacol. 148 (2006) 123-135
24. Kogan N.M. Cannabinoids and cancer. Mini Rev. Med. Chem. 5 (2005) 941-952
25. Rueda D., Navarro B., Martinez-Serrano A., Guzman M., and Galve-Roperh I. The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. J. Biol. Chem. 277 (2002) 46645-46650
26. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinalidi-Carmona M., Le Fur G., and Casellas P. Activation of mitogen activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312 (1995) 637-641
27. Bouaboula M., Pointo-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., Calandra B., Le Fur G., and Casellas P. Signalling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237 (1996) 704-711
28. Gomez del Pulgar T., Velasco G., and Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J. 347 (2000) 373-396
29. Sanchez M.G., Ruiz-Llorente L., Sanchez A.M., and Diaz-Laviada I. Activation of phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 cannabinoid receptors expressed in prostate PC-3 cells. Involvement of Raf-1 stimulation and NGF induction. Cell. Signal. 15 (2003) 851-859
30. Galve-Roperh I., Rueda D., Gomez del Pulgar T., Velasco G., and Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB1 cannabinoid receptor. Mol. Pharmacol. 62 (2002) 1385-1392
31. Hart S., Fischer O.M., and Ullrich A. Cannabinoids induce cancer cell proliferation via tumour necrosis factor α-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64 (2004) 1943-1950
32. Sanchez C., Galve-Roperh I., Rueda D., and Guzman M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta-9-tetrahydrocannabidiol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. 54 (1998) 834-843
33. Huffman J.W., Liddle J., Yu S., Aung M.M., Abood M.E., Wiley J.L., and Martin B.R. 3-(1′,1′-Dimethylbutyl)-1-deoxy-D8-THC and related compounds: Synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 7 (1999) 2905-2914
34. McPartland J.M., Glass M., and Pertwee R.G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol. 152 (2007) 583-593
35. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrara P., Soubrie P., Breliere J.C., and Le Fur G. SR141716, A a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
36. Rinaldi-Carmona M., Barth F., Milan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., and Le Fur G. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284 (1998) 644-650
37. Blazquez C., Casanova M.L., Planas A., Gomez del Pulgar T., Villanueva C., Fernandez-Acenero M.J., Agagones J., Huffman J.W., Jorcano J.L., and Guzma M. Inhibition of tumour angiogenesis by cannabinoids. FASEB J. 17 (2003) 529-531
38. Sarfaraz S., Afaq F., Adhami V.M., and Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65 (2005) 1635-1641
39. McAllister S.D., Chan C., Taft R., Luu T., Abood M.E., Moore D.H., Aldape K., and Yount G. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J. Neurooncol. 74 (2005) 31-40
40. Ellert-Miklaszewska A., Kaminska B., and Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of bad protein. Cell. Signal. 17 (2005) 25-37
41. Sarfaraz S., Afaq F., Adhami V.M., Malik A., and Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J. Biol. Chem. 281 (2006)
42. Caffarel M., Sarrio D., Palacios J., Guzman M., and Sanchez C. Δ9-Tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res. 66 (2006) 6615-6621
43. Grimaldi C., Pisanti S., Laezza C., Malfitano A.M., Santoro A., Vitale M., Caruso M.G., Notarnicola M., Iacuzzo I., Portella G., Di Marzo V., and Bifulco M. Anandamide inhibits adhesion and migration of breast cancer cells. Exp. Cell Res. 312 (2006) 363-373
44. Laezza C., Pisanti S., Crescenzi E., and Bifulco M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett. 580 (2006) 6076-6082
45. Ligresti A., Moriello A.S., Starowicz K., Matias I., Pisanti S., De Petrocellis L., Laezza C., Portella G., Bifulco M., and Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther. 318 (2006) 1375-1387
46. McKallip R.J., Nagarkatti M., and Nagarkatti P.S. Δ9-Tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumour immune response. J. Immunol. 174 (2005) 3281-3289
47. Berdyshev E.V. Cannabinoid receptors and the regulation of the immune response. Chem. Phys. Lipids 108 (2000) 169-190
48. Xu H., Cheng C.L., Chen M., Manivannan A., Cabay L., Pertwee R.G., Coutts A., and Forrester J.V. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinits. J. Leukoc. Biol. 82 (2007) 532-541
49. Preet A., Ganju R.K., and Groopman J.E. Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27 (2008) 339-346
50. Guzman M., Duarte M.J., Blazquez C., Ravina J., Rosa M.C., Galve-Roperh I., Sanchez C., Velasco G., and Gonzalez-Feria L. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Brit. J. Cancer. 95 (2006) 197-203
51. Xu X., Liu Y., Huang S., Liu G., Xie C., Zhou J., Fan W., Li Q., Wang Q., Zhong D., and Miao X. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Gen. Cytogen. 171 (2006) 31-38